CuraCell Holding

Curacell develops cell based immunotherapies for cancer treatment focusing on TILs (Tumor Infiltrating Lymphocytes), an investigational therapy aimed at a durable cure for solid tumor cancers.

The company is initiating its first clinical program targeting indications with high prevalence and the potential to make a significant impact on cancer patients worldwide.